Clinical Trials Browser

Phase 1/2 × Completed × trilaciclib × Clear all

NCT02514447 2025-09-25

Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy

Phase 1/2 Completed

123 enrolled 46 charts

Small Cell Lung Carcinoma

NCT02499770 2020-08-21

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)

Phase 1/2 Completed

122 enrolled 62 charts

Small Cell Lung Carcinoma